Drug General Information (ID: DDI4MRA9XB)
Drug Name			Human C1-esterase inhibitor		Drug Info		Peginesatide		Drug Info
Drug Type		Protein/peptide				Protein/peptide
Therapeutic Class		Hereditary Angioedema Agents				Recombinant Human Erythropoietins

Mechanism of Human C1-esterase inhibitor-Peginesatide Interaction (Severity Level: Moderate)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Human C1-esterase inhibitor				Peginesatide
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Human C1-esterase inhibitor and Peginesatide

Recommended Action
Management		Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain shortness of breath rapid pulse pain, swelling, and/or discoloration in an arm or leg and numbness or weakness on one side of the body.

References
1	Product Information. Berinert (complement C1 esterase inhibitor). CSL Behring, King of Prussia, PA.
2	Product Information. Ruconest (conestat alfa). Valeant Pharmaceuticals, Costa Mesa, CA.
3	Gandhi PK, Gentry WM, Bottorff MB "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy 32 (2012): 902-9. [PMID: 23033229]